The Patent Finder
AB

Abelzeta Inc.

First filing 2019
OverviewNotableFeesChangesFamiliesPatent listSources & methods

21 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2038. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2038
Next term end
7
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 11, 2027
    The maintenance fee for Reagent and Method for Fluorescence Quantitative Real-Time PCR Detection of RCL (US 11,697,848) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 17, 2026

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,066,457Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
In force
 · High confidence
In forceHigh confidence
US 11,472,858Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
In force
 · Low confidence
In forceLow confidence
US 11,608,369Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
In force
 · High confidence
In forceHigh confidence
US 11,618,778Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
In force
 · High confidence
In forceHigh confidence
US 12,583,903Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
In force
 · Low confidence
In forceLow confidence
US 12,747,279Construction of Chimeric Antigen Receptor Targeting CD20 Antigen and Activity Identification of Engineered T Cells Thereof
In force
 · High confidence
In forceHigh confidence
US 11,363,812Cell Freezing Medium for Clinical Use
In force
 · High confidence
In forceHigh confidence
US 12,356,981Cell Freezing Medium for Clinical Use
In force
 · High confidence
In forceHigh confidence
US 12,338,494Reagent and Method for Fluorescence Quantitative Real-Time PCR Detection of RCL
In force
 · High confidence
In forceHigh confidence
US 11,697,848Reagent and Method for Fluorescence Quantitative Real-Time PCR Detection of RCL
In force
 · High confidence
In forceHigh confidence
10 of 21 patents shown.
Pro members see all 21.
Pro members: see all 21 patents
Also on record, not counted in the 21: 15 applications pending · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited